Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/3/2026Positive
ACAD
ACADIA Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.83B
P/E Ratio
12.56
EPS
$2.23
Beta
0.86
52W High
$30.96
52W Low
$19.69
50-Day MA
$27.29
200-Day MA
$24.47
Dividend Yield
—
Profit Margin
33.40%
Forward P/E
27.55
PEG Ratio
50.86
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.14B |
| Gross Profit (TTM) | $706.66M |
| EBITDA | $98.39M |
| Operating Margin | 12.30% |
| Return on Equity | 35.70% |
| Return on Assets | 3.64% |
| Revenue/Share (TTM) | $6.69 |
| Book Value | $7.59 |
| Price-to-Book | 3.67 |
| Price-to-Sales (TTM) | 4.24 |
| EV/Revenue | 3.439 |
| EV/EBITDA | 39.80 |
| Quarterly Earnings Growth (YoY) | 13.30% |
| Quarterly Revenue Growth (YoY) | 16.40% |
| Shares Outstanding | $172.31M |
| Float | $128.35M |
| % Insiders | 0.33% |
| % Institutions | 99.88% |
Historical Volatility
HV 10-Day
32.41%
HV 20-Day
35.42%
HV 30-Day
40.48%
HV 60-Day
35.76%
HV Rank
68.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($34.00 target)
4
Strong Buy12
Buy4
Hold1
SellLatest News
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
Zacks Investment Research8/24/2026Positive
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad.
Business Wire8/24/2026Neutral
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data
ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.
MarketBeat8/12/2026Positive
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Zacks Investment Research8/7/2026Positive
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?
Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Investment Research8/6/2026Positive
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.
Zacks Investment Research8/5/2026Positive
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
Seeking Alpha8/5/2026Neutral
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q.
Business Wire8/4/2026Neutral
HRMY or ACAD: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research7/30/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACAD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026